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Translesion DNA synthesis (TLS) mediated by low-fidelity
DNApolymerases is an essential cellularmechanism for bypass-
ing DNA lesions that obstruct DNA replication progression.
However, the access of TLS polymerases to the replication
machinery must be kept tightly in check to avoid excessive
mutagenesis. Recruitment of DNA polymerase  (Pol ) and
other Y-family TLS polymerases to damagedDNA relies on pro-
liferating cell nuclear antigen (PCNA) monoubiquitylation and
is regulated at several levels. Using a microscopy-based RNAi
screen, here we identified an important role of the SUMOmod-
ification pathway in limiting Pol  interactions with DNA dam-
age sites in human cells. We found that Pol  undergoes DNA
damage- and protein inhibitor of activated STAT 1 (PIAS1)-de-
pendent polySUMOylation upon its association with monou-
biquitylated PCNA, rendering it susceptible to extraction from
DNA damage sites by SUMO-targeted ubiquitin ligase (STUbL)
activity. Using proteomic profiling, we demonstrate that Pol is
targeted for multisite SUMOylation, and that collectively these
SUMO modifications are essential for PIAS1- and STUbL-me-
diated displacement of Pol  from DNA damage sites. These
findings suggest that a SUMO-driven feedback inhibitionmech-
anism is an intrinsic feature of TLS-mediated lesion bypass
functioning to curtail the interaction of Pol  with PCNA at
damaged DNA to prevent harmful mutagenesis.
Numerous DNA damaging insults are inflicted daily upon
the genomes of all living cells (1). If left unrepaired, these lesions
can modify the functionality of the genetic material and
adversely affect organismal fitness (2). Cellular genomes are
particularly vulnerable to DNA damage encountered during
chromosomal DNA replication. Genome duplication generally
proceeds in a highly processive and accuratemanner, due to the
extremely high fidelity and proofreading activity of normal,
replicative DNA polymerases (3). However, because these po-
lymerases are unable to accommodate most damaged or mod-
ified DNA structures in their active sites, the occurrence of
DNA lesions in S phase may obstruct the progression of the
advancing replicationmachinery. This presents a serious threat
to genome stability as the stalled replication fork may collapse,
potentially giving rise to highly cytotoxic DNA double-strand
breaks and gross chromosomal instability (4). To mitigate such
danger, cells in all domains of life have evolved DNA damage
bypass or tolerance strategies enabling the genome duplication
machinery to replicate past fork-blocking lesions (5).
The predominant DNAdamage bypassmechanism in higher
eukaryotes involves specialized translesion DNA synthesis
(TLS) polymerases, which unlike replicative DNA polymerases
are able to incorporate nucleotides opposite lesions and thus
replicate damaged DNA without repairing it (5, 6). However,
because TLS polymerases have flexible active sites and lack
proofreading activity, their fidelities are orders of magnitude
lower than those of replicative DNA polymerases, hence TLS is
muchmore error-prone than normal DNA replication (5). Due
to these inherent properties, TLS plays a double-edged role in
genome stability maintenance: on the one hand, the bypass of
DNA lesions during replication by damage-tolerant polymer-
ases provides cells with the flexibility needed to avoid the
potentially much more severe consequences of collapsed repli-
cation forks. On the other hand, TLS is a mutagenic process,
whose dysregulation has a well-established role in the develop-
ment of cancer and other severe disorders (7–9). Accordingly,
TLS must be kept tightly in check at all times, and multiple
regulatory mechanisms have evolved to enable a carefully bal-
anced level of TLS that allows DNA lesion bypass while sup-
pressing excessive mutagenesis.
Mammalian cells encode a range of TLS polymerases, of
which several of the most important ones belong to the Y-fam-
ily of DNA polymerases (6). Among these, DNA polymerase 
(Pol ) bypasses cyclobutane pyrimidine dimers (CPDs), the
major DNA lesion induced by UV light, with high accuracy and
collaborates with Pol  in replication past cisplatin-induced
DNA intra-strand cross-links (6, 10–16). Reflecting its critical
physiological importance, Pol  dysfunctionality leads to a var-
iant form of xeroderma pigmentosum (XPV), a disorder char-
acterized by a high incidence of pigmentation changes, sun sen-
sitivity, and skin cancer, likely caused by the compensatory
action of more mutagenic back-up TLS polymerases (17–19).
Activation of TLS entails the replacement of a replicative
DNA polymerase bound to the proliferating cell nuclear anti-
gen (PCNA) clamp with a TLS polymerase. Multilayered regu-
latorymechanisms, in which signaling by ubiquitin and ubiqui-
tin-like modifiers (UBLs) has a central role, exert tight control
over TLS polymerase recruitment to damaged DNA (20, 21). In
particular, DNA damage-dependent PCNA monoubiquityla-
tion at Lys-164 by the RAD18-RAD6 E3 ubiquitin ligase com-
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plex has a key function in stimulating TLS by generating a bind-
ing platform for Y-family TLS polymerases, which harbor both
PCNA-interacting protein (PIP) boxes and ubiquitin-binding
motifs that enable them to preferentially interact with monou-
biquitylated PCNA and displace replicative polymerases (22–
26). High affinity of Pol  for monoubiquitylated PCNA, visible
in cells as the formation of discrete nuclear Pol  foci upon
DNA damage, is mediated by a C-terminal ubiquitin-binding
zinc finger (UBZ) domain, three PIP boxes and a nuclear local-
ization signal (NLS) (25, 27–32). Due to the error-prone nature
and lack of processivity of TLS polymerases, they must be
replaced with a replicative DNA polymerase following damage
bypass in a second polymerase exchange that is also subject to
elaborate regulatory control. Several mechanisms, including
PCNA deubiquitylation by USP1 and the action of a number of
factors including CRL4CDT2 and PAF15, and post-translational
modifications (PTMs) by phosphorylation, ubiquitylation, and
O-GlcNAcylation, directly or indirectly contribute to limiting
Pol  interactions with DNA damage sites (33–39), but the
relative contributions and precise mechanistic underpinnings
of these processes are not yet fully understood.
Given the critical importance of limiting interactions of Pol
and other TLS polymerases with PCNA at damaged DNA to
avoid unwanted genetic changes, we used a high-throughput
imaging-based screen as an unbiased approach to identify sig-
naling processes controlling the access of Pol toDNAdamage
sites in human cells. We found that SUMOylation impinging
directly on Pol  bound to PCNA at DNAdamage sites plays an
important role in limiting this interaction. We established that
this regulatory circuit involves DNA damage-dependentmulti-
site SUMOylation of Pol  that renders it susceptible to extrac-
tion from DNA damage sites by the action of SUMO-targeted
ubiquitin ligases (STUbLs). These findings suggest the exist-
ence of a SUMO-driven negative-feedback loop operating to
limit the association of Pol with PCNA at damaged DNA and
prevent unscheduled mutagenesis.
Results
Amicroscopy-based RNAi screen reveals SUMO-dependent
regulation of Pol association with DNA damage sites
To gain better insights into how signaling by ubiquitin and
UBLs control TLS, we performed a high-throughputmicrosco-
py-based screen for regulators of Pol  association with dam-
aged DNA, using a human U2OS osteosarcoma cell line engi-
neered to stably expressGFP-taggedPol at a low level (40) and
an siRNA library targeting 1251 genes involved in ubiquitin-
and UBL-mediated signaling (41) (Fig. 1A). To this aim,
siRNA-transfected cells were treated with cisplatin to induce
DNA damage, and acquisition and quantification of the result-
ing GFP-Pol  foci were performed using quantitative image-
based cytometry (QIBC) (42), allowing for the ranking of all
siRNAs according to their impact on GFP-Pol  foci counts
(Fig. 1, A and B; Table S1). As expected, siRNAs targeting
RAD18 and RAD6, which catalyze PCNA monoubiquitylation
and are required for Pol  recruitment to DNA damage sites
(22, 24), were among the strongest suppressors of cisplatin-
inducedGFP-Pol foci, whereas knockdownof the PCNAdeu-
biquitinase USP1 led to increased GFP-Pol  foci formation
(Fig. 1B; Table S1), validating our experimental screen setup.
Consistent with previouswork by others and us (40, 43), knock-
downof the SPRTNprotease also enhanced PolDNAdamage
foci counts (Table S1). In addition to these positive controls, the
siRNA screen revealed a range of additional Ub/UBL signaling
factors, whose depletion markedly enhanced GFP-Pol  re-
cruitment to cisplatin-induced DNA damage, suggesting
potential functions of these proteins in restricting Pol  inter-
action with damaged DNA (Fig. 1B; Table S1). Validation
screens for the strongest hits using siRNAs from the primary
screen and independent siRNAs subsequently revealed a range
of high-confidence hits whose depletion enhanced GFP-Pol 
association with sites of cisplatin-induced DNA damage (Fig.
1C; Table S2). Notably, these included both the SUMO E1
(SAE1 andUBA2) and E2 (UBC9) enzymes that are essential for
SUMOylation and whose individually reduced expression
strongly increased both Pol  foci counts and intensity (Fig. 1,
B–D; Fig. S1, A and B), suggesting a potential function of the
SUMO modification pathway in limiting Pol  interactions
with DNA damage sites. In agreement with this notion, a time
course analysis showed that depletion of SAE1, UBA2, orUBC9
led to amarkedly elevated proportion and intensity of cisplatin-
induced GFP-Pol  foci that persisted long after these struc-
tures returned to baseline levels in control cells (Fig. 1E; Fig.
S1C). This suggested that SUMOylation has a role in promoting
Pol clearance from sites of cisplatin-inducedDNAdamage. In
addition to bypassing cisplatin-induced DNA intra-strand
cross-links, Pol also performs highly accurate insertion across
CPDs induced by UV radiation (44). We therefore asked if
down-regulation of SAE1, UBA2, or UBC9 would also enhance
Pol  accumulation at sites of UV-induced DNA damage.
Indeed, depleting either of these factors increased endogenous
Pol  foci number and intensity, as well as overall Pol  chro-
matin association, upon exposure to UV (Fig. 1, F and G).
Importantly, acute suppression of SUMOylation by the small-
molecule SUMO E1 enzyme inhibitor ML-792 (SUMOi) (45)
phenocopied the effect of depleting SAE1, UBA2, or UBC9, by
enhancing UV-induced Pol  foci formation in U2OS cells,
MRC5normal lung fibroblasts, and nontransformedRPE-1 ret-
inal pigment epithelial cells (Fig. 1,H and I; Fig. S1D). Together,
these data support a role for SUMO-mediated signaling in
antagonizing Pol  interactions with DNA damage sites that is
operational in both normal and cancer cells.
Pol is polySUMOylated in response to DNA damage
Wenext set out to address howSUMOylation regulates Pol
interactions with DNA damage sites. First, we established that
siRNA-mediated depletion of UBA2, SAE1, or UBC9 had no
discernible effect on cell cycle profiles and PCNAmonoubiqui-
tylation levels (Fig. S2, A and B), indicating that the enhanced
association of Polwith sites of DNAdamage in these cells was
not an indirect consequence of altered cell cycle progression or
DNA damage levels. We therefore considered the possibility
that the impact of SUMOylation onPol associationwith dam-
aged DNA might involve direct SUMO modification of Pol 
itself. Indeed, GFP-Pol  pulldowns under denaturing condi-
tions revealed robustUV-inducedmodification of Pol by both
SUMOylation limits Pol interaction with DNA damage sites
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SUMO1 and SUMO2/3 (Fig. 2, A and B). Pol  has previously
been reported to undergo SUMOylation on Lys-163 in unper-
turbed cells overexpressing both Pol  and SUMO isoforms
(46). Under our experimental conditions, involving endoge-
nous SUMOand ectopic Pol expressed at low levels, we found
that Pol  was predominantly modified by polySUMOylation
upon DNA damage (Fig. 2, A–C). Although a point mutation
preventing SUMOylation of Lys-163 (K163R) abolished Pol 
monoSUMOylation, consistent with previous findings (46), it
had no detectable impact on UV-induced GFP-Pol  poly-
SUMOylation (Fig. S2C), implying that this modification is not
specifically targeted to Lys-163. The onset of UV-induced Pol
polySUMOylation correlated with the appearance of UV-in-
duced Pol  foci (Fig. S2D) and the time needed for Pol  to
encounter and bypass UV lesions (6, 47). This suggests that Pol
 becomes susceptible to SUMOylation upon its recruitment to
PCNA at damaged DNA. Consistent with this notion, prevent-
ing Pol  recruitment to monoubiquitylated PCNA by knock-
down of RAD18 abrogated UV-induced GFP-Pol  poly-
SUMOylation (Fig. 2D).We next screened for SUMOE3 ligases
involved in DNA damage-dependent Pol  polySUMOylation.
Individual depletion of known SUMO E3s suggested PIAS1 as
the prospective ligase (Fig. S2E). We substantiated this obser-
vation using several independent PIAS1 siRNAs that abolished
UV-induced Pol  polySUMOylation but did not noticeably
affect cell cycle status and PCNA monoubiquitylation (Fig. 2E;
Fig. S2, B and F). Consistent with a causal role of PIAS1 in
promoting DNA damage-induced Pol  SUMOylation, PIAS1
but not PIAS4, another DDR-associated SUMO E3 ligase (48),
co-immunoprecipitated with GFP-Pol  in a manner that was
stimulated by UV radiation (Fig. 2F). We conclude that Pol 
undergoes PIAS1-dependent polySUMOylation upon its DNA
damage-induced association with PCNA.
PIAS1 and SUMO-targeted ubiquitin ligases regulate Pol
interactions with DNA damage sites
We next analyzed whether and how PIAS1-dependent poly-
SUMOylation of Pol  impacts its interaction with DNA dam-
age sites. Consistent with a role of SUMOylation in limiting Pol
 retention at damaged DNA, we found that like UBA2 or
UBC9 knockdown, depletion of PIAS1 enhanced GFP-Pol 
foci number and intensity in U2OS cells (Fig. 3A; Fig. S3A).
Similar observations weremade for endogenous Pol inMRC5
cells (Fig. 3B). Moreover, overexpression of WT PIAS1 but not
a catalytically inactive point mutant (C350S) led to quantitative
removal of UV-induced Pol  foci (Fig. 3, C and D), suggesting
that PIAS1-mediated polySUMOylation of Pol  promotes its
dissociation from PCNA at DNA damage sites. SUMOylation
of chromatin-bound proteins can trigger their subsequent
extraction via SUMO-targeted ubiquitin ligases (STUbLs) (49–
51), and we therefore asked whether the known human
STUbLs, RNF4 and RNF111, might be effectors of PIAS1
SUMO E3 ligase-mediated dissociation of Pol  from DNA
damage foci. In support of this possibility, knockdown of RNF4
or RNF111 using independent siRNAs enhanced GFP-Pol 
foci counts and intensity (Fig. 3E; Fig. S3, B–D). Moreover, loss
of RNF4 or RNF111 strongly enhancedUV-induced Pol poly-
SUMOylation accompanied bymodestly elevated Pol expres-
sion levels (Fig. 3F), further indicating that impaired STUbL
functionality interferes with the proper processing of SUMO-
modified Pol . To determine whether the potential roles of
RNF4 and RNF111 in regulating Pol  interactions with DNA
damage sites require their STUbL activities, we analyzed GFP-
Pol  foci formation in cells overexpressing RNF4 or RNF111
WT or mutant forms containing inactivating substitutions
within their SUMO-interacting (*SIM) or catalytic RING
(*RING) motifs. Supporting a direct involvement of RNF111
STUbL activity in promoting extraction of SUMO-modified
Pol  from damaged chromatin, we found that overexpressed
RNF111WT but not the *SIM and *RINGmutants suppressed
GFP-Pol  localization to DNA damage sites (Fig. 3, G and H).
By contrast, both WT and mutant alleles of overexpressed
RNF4 impaired GFP-Pol  foci formation after UV (Fig. 3, G
and H), suggesting that modulation of RNF4 functionality
impacts Pol  association with damaged DNA via amechanism
that is independent of its STUbL activity and whose precise
basis awaits to be established. Finally, using independent
siRNAs we validated that depletion of RNF111 led to an
increased association of endogenous Pol  with DNA damage
sites and UV-damaged chromatin (Fig. 3, I and J). Collectively,
the data suggest that PIAS1-dependent polySUMOylation of
Pol may trigger its STUbL-mediated ubiquitylation and con-
comitant dissociation from DNA damage sites.
Multisite SUMOylation of Pol underlies its PIAS1- and
RNF111-dependent clearance fromDNA damage sites
To directly analyze the role of SUMOylation in constraining
Pol  association with damaged DNA, we sought to map the
SUMO modification sites in Pol . Using an augmented
K0-SUMOproteomic strategy coupledwith deepMSdata anal-
ysis (52), we identified 19 SUMOylation sites in human Pol 
(Fig. 4, A and B; Fig. S4; Table S3), which is consistent with its
observed polySUMOylation in biochemical experiments (Fig.
2, A–C) and provides direct evidence that endogenous Pol  is
Figure 1. A microscopy-based screen reveals SUMO-dependent regulation of Pol  association with DNA damage sites. A, experimental set-up of high-
throughputmicroscopy-based screen forubiquitin andUBL signalingnetwork components regulatingPol interactionwith sitesof cisplatin-inducedDNAdamage.
See text for details. B, results of the screen outlined in A. Scatter plot shows ranked Z-scores of cisplatin-induced GFP-Pol  foci counts of all siRNAs in the library (2
siRNAspergene),determinedbyQIBCanalysis.Controls (RAD18-RAD6andUSP1)are indicated ingreenand red, respectively.SUMOE1(SAE1andUBA2)andE2(UBC9)
enzymesare indicated inorange. SeealsoTableS1.C,workflowofprimaryandvalidationscreens, andhit selection. SeealsoTableS2.D, resultsof thevalidationscreen
analyzingGFP-Pol focicount inU2OS/GFP-Polcells transfectedwiththe indicatedsiRNAs,exposedtocisplatin for6h,andfixed16hlaterandquantifiedusingQIBC
analysis (mean  S.D.; n  3 independent experiments; 294 cells quantified per condition). E, results of validation screen analyzing kinetics of GFP-Pol  foci
formation in cells treatedas inD (meanS.D.;n3 independent experiments;3,000 cells quantifiedper condition). F, representative imagesof endogenousPol
foci formation in U2OS cells transfected with the indicated siRNAs and exposed to UV. Scale bar, 10m. G, immunoblot analysis of chromatin-enriched fractions of
U2OScells treatedas inF.H,U2OS/GFP-PolcellswerepreincubatedornotwithSUMOi for30min,exposedtoUV(20J/m2),andcollected6h later.ThesumofGFP-Pol
 foci intensity per nucleuswas quantified byQIBC (mean S.E.M.; n 3 independent experiments;7,482 cells quantified per condition). I, representative images
of endogenous Pol foci formation in U2OS, hTert RPE-1, andMRC5 cells treated as inH. Scale bar, 10m.
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modified by multisite SUMOylation. Although some of these
sites are located within the polymerase domain, the majority of
mapped Pol  SUMOylation sites cluster in its C-terminal half
containing a NLS as well as PIP and UBZ motifs required for
targeting Pol  to DNA damage sites (Fig. 4B). The identifica-
tion of these SUMOylation sites provided an opportunity to
directly address whether SUMOylation of Pol  promotes its
turnover fromDNAdamage sites, andwe therefore generated a
Figure 2. DNAdamage-dependent polySUMOylation of Pol. A,U2OS or U2OS/GFP-Pol cells were left untreated or exposed to UV, lysed, and subjected
to GFP immunoprecipitation (IP) under denaturing conditions followed by immunoblotting (IB) with the indicated antibodies. B, as in A, but using SUMO1
antibody for immunoblotting. C, PolpolySUMOylation at different time points after UV exposurewas analyzed as inA.D,U2OS/GFP-Pol cells treated or not
with RAD18 siRNA and UV as indicated were processed for analysis of Pol  polySUMOylation as in A. E, as in A, using the indicated PIAS1 siRNAs. F, U2OS or
U2OS/GFP-Pol  cells left untreated or exposed to UV were lysed and subjected to GFP IP under native conditions and immunoblotted with the indicated
antibodies.
SUMOylation limits Pol interaction with DNA damage sites
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Pol mutant in which all of the 19 SUMOylated lysine residues
were mutated to arginine, to prevent their SUMO-dependent
modification.We additionally introduced an arginine substitu-
tion at Lys-163, the previously reported Pol SUMOylation site
(46) that did not, however, pass the significance threshold in
our MS data analysis (Table S3). Substituting the 20 lysine res-
idues with arginines (20KR) affected the subcellular localiza-
tion of Pol (data not shown), likely due to theK682Rmutation
located within its NLS that has previously been reported to
impair nuclear localization (Fig. 4B) (25). To circumvent this
issue, we introduced an NLS into the GFP-Pol WT and 20KR
constructs, resulting in their exclusively nuclear localization
(see Fig. 4D). Pulldowns of the GFP-Pol  alleles under dena-
turing conditions confirmed that the 20KR mutations largely
abolished UV-induced polySUMOylation of Pol  but not its
functionality in DNA damage bypass per se (Fig. 4C; Fig. S3, E
and F). Prompted by this observation, we then tested whether
the lack of DNA damage-induced Pol  SUMOylation would
render it resistant to PIAS1- and RNF111-mediated displace-
ment from DNA damage sites. Importantly, the 20KR mutant
fully retained the ability to accumulate in UV-induced nuclear
foci (Fig. 4D). However, unlikeWT Pol  the 20KRmutant was
insensitive to the ability of elevated PIAS1 catalytic activity to
suppress Pol  foci formation (Fig. 4, D and E). Similarly, we
found that overexpression of WT RNF111 but not the *RING
and *SIM mutants reduced GFP-Pol  WT association with
DNA damage sites, whereas the 20KRmutant was refractory to
the impact of elevated RNF111 STUbL activity (Fig. 4, F andG).
Together, these data lend strong support to the notion that
UV-induced, PIAS1-dependent multisite SUMOylation of Pol
 promotes its STUbL-mediated turnover from DNA damage
sites, providing a potential means to curb Pol  activity during
DNA damage bypass and thereby mitigate the risk of unsched-
uled mutagenesis.
Discussion
The access of Pol  and other low-fidelity TLS polymerases
to the DNA synthesis machinery must be tightly regulated to
avoid unscheduledmutagenesis, and PTMshave been shown to
control TLS activity at several levels. Based on an unbiased
screen for PTM-mediated regulators of Pol  interaction with
DNA damage sites, we here provide evidence that one cellular
mechanism for limiting Pol -mediated TLS involves a built-in
feedback inhibition circuit driven by SUMOylation. We show
that Pol  undergoes robust polySUMOylation concomitant
with, and dependent on, its recruitment to monoubiquitylated
PCNA at DNA damage sites. These SUMO modifications in
turn render Pol  susceptible to STUbL-mediated extraction
from DNA damage sites, thereby helping to ensure that direct
Pol  interactions with PCNA at damaged DNA are kept highly
dynamic and transient. Indeed, it has previously been shown
that the residence time of human Pol  in nuclear foci is less
than 1 s (27). The notion that Pol becomes SUMOylated upon
its recruitment to DNA-loaded PCNA is well-aligned with
recent work demonstrating that compared with mature chro-
matin, the protein landscape around newly replicated DNA is
enriched in SUMO modifications (53, 54). Thus, high local
SUMOylation activity in the context of the replisomemay con-
tribute to an environment in which the docking of TLS poly-
merases and other auxiliary DNA replication factors can be
carefully controlled and dynamically regulated in accordance
with the status and integrity of ongoing DNA synthesis. It is
possible that such a SUMO-mediated regulatory scheme could
operate more broadly within TLS, as we have observed that
other Y-family polymerases can also be modified by polySU-
MOylation in cells.3 Notably, our augmented proteomic strat-
egy for mapping SUMOylation sites revealed that Pol 
SUMOylation impacts an extensive range of lysine residues dis-
tributed throughout its domains, suggesting a high degree of
promiscuity in the modification of individual sites. This obser-
vation further supports a scenario in which the replisome har-
bors high SUMOylation activity toward solvent-exposed lysine
residues in incoming factors that allows for their subsequent
turnover in amanner thatmay be largely non-site specific. Con-
sistent with this idea, we found that simultaneous mutation of
all mapped SUMOylation sites in Pol , but not subsets of
SUMO-conjugation sites, is necessary to render Pol  refrac-
tory to the ability of elevated PIAS1 and STUbL activity to pro-
mote its extraction from DNA damage sites.1
A common mechanism by which SUMO-modified proteins
are evicted from chromatin entails their STUbL-mediated
ubiquitylation. Previous work by others and us (49, 55–58)
demonstrated important regulatory roles of the human
STUbLs RNF4 and RNF111 in promoting extraction of a range
of genome stability maintenance factors, including XPC,
FANCD2-FANCI, RPA, and MDC1, from DNA damage sites.
The findings reported here suggest that by driving the turnover
of SUMOylated Pol  fromDNA damage sites the involvement
of STUbL activity in theDNAdamage response extends toTLS,
although the depletion of RNF4 or RNF111 enhanced Pol foci
number and intensity to a milder extent than knockdown of
3 C. Guerillon, S. Smedegaard, I. A. Hendriks, M. L. Nielsen, and N. Mailand,
unpublished observations.
Figure3.PIAS1andSTUbLactivitypromotesPoldisplacement fromDNAdamagesites.A,GFP-Pol foci count inU2OS/GFP-Pol cells transfectedwith
the indicated siRNAs, exposed to UV, and fixed 6 h later was quantified using QIBC analysis (mean  S.E.M.; n  3 independent experiments; 1991 cells
quantified per condition). B, representative images of endogenous Pol foci formation inMRC5 cells transfectedwith the indicated siRNAs and exposed toUV.
Scale bar, 10m.C, representative images of U2OS/GFP-Pol cells transfectedwith the indicatedHA-PIAS1 expression plasmids or empty vector (eV), exposed
to UV, and immunostained with HA antibody. Scale bar, 10 m. D, quantification of data in C (mean  S.E.M.; n  3 independent experiments; 50 cells
analyzed per condition). E, GFP-Pol  foci count in U2OS/GFP-Pol  cells transfected with the indicated siRNAs analyzed as in A (mean  S.E.M.; n  4
independent experiments;1254 cells quantified per condition). F, U2OS/GFP-Pol  cells treated with the indicated RNF4 or RNF111 siRNAs and exposed to
UVwere lysed and subjected to GFP IP under denaturing conditions followed by immunoblotting (IB) with the indicated antibodies. G, representative images
of U2OS/GFP-Pol cells transiently transfectedwith the indicated RNF4 or RNF111 expression constructs or empty vector (eV), and treated as in C. Scale bar, 10
m. H, quantification of data in G (mean S.E.M.; n 3 independent experiments;50 cells analyzed per condition). I, immunoblot analysis of chromatin-
enriched fractions of U2OS cells transfected with the indicated RNF111 siRNAs and exposed to UV. Association of endogenous Pol  with UV-damaged
chromatin (normalized to Histone H3 abundance) was quantified using ImageJ. J, representative images of endogenous Pol  foci formation in MRC5 cells
transfected with the indicated RNF111 siRNAs and exposed to UV. Scale bar, 10 m.
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SUMO E1 and E2 enzymes. This raises the possibility that
SUMOylated Pol  may also be susceptible to displacement
from monoubiquitylated PCNA via other mechanisms. We
found that whereas the association of Pol  with DNA damage
foci was responsive to bothmanipulation of RNF4 and RNF111
status, only RNF111 promoted Pol  dissociation from these
locales in a manner that depended on the integrity of its RING
and SIM domains, as expected from the bona fide action of a
STUbL. It is possible that altering RNF4 functionality could
impact Pol  retention at damaged DNA via a more general,
indirect effect on SUMOpathway homeostasis. In line with this
notion, both UBC9 and a number of E3 SUMO ligases have
been reported to be direct substrates of RNF4 ubiquitin ligase
activity (59). Interestingly, recent work suggested that RNF111
shows a preference for polySUMO2/3 chains capped by
SUMO1 (60), in good agreement with our finding that Pol  is
modified by both SUMO2/3 and SUMO1 in response to UV.
Our observation that DNA damage-induced Pol  poly-
SUMOylation requires RAD18 and the PIAS1 SUMO E3 ligase
is consistent with recent findings reporting a specific role of Pol
 SUMOylation at Lys-163 in promoting its interaction with
replication forks (46). However, whereas our biochemical data
support monoSUMOylation of Pol  at Lys-163, our deep MS-
based profiling of SUMOylation sites on endogenous proteins
and biochemical assays using ectopic Pol  expressed at low
levels in cells clearly show that the pattern of Pol  SUMO
modifications in cells is considerably more complex, involving
multisite SUMOylation that impacts at least 19 lysine residues
and is highly responsive to DNA damage. Interestingly, muta-
tions disrupting two of these SUMO modification sites (Lys-
224 and Lys-589) have been identified in XPV patients (61–63).
Together with previous data (46), these findings suggest that at
least two modes of SUMO-mediated regulation of Pol  are
operational in cells. First, monoSUMOylation of Pol  on Lys-
163may promote its associationwith the replicationmachinery
in undamaged cells (46). Second, our data show that Pol 
undergoes DNA damage-dependent polySUMOylation on
multiple lysine residues in amanner that is independent of Lys-
163 and has an important role in preventing excessive Pol 
interactions with DNA damage sites. Future work should
address in more detail the mechanisms and significance of the
complex andmultifaceted roles of SUMOylation in controlling
the access of Pol , and possibly other TLS polymerases, to
different DNA structures. In summary, our findings suggest
that stimulation of Pol -dependent DNA damage bypass trig-
gers its own inactivation via a SUMO-mediated feedback inhi-
bition mechanism, offering a simple yet efficient means of
restraining TLS activity to avoid the harmful consequences of
excessive mutagenesis.
Experimental procedures
Plasmids and siRNAs
Plasmid expressing eGFP-tagged human Pol  WT was a
kind gift fromA. Lehmann (University of Sussex, UK). Plasmids
encoding Strep/HA-RNF111 WT, *RING and *SIM, and
mCherry-RNF4 WT, *RING and *SIM were described previ-
ously (49, 55). A cDNA encoding Pol  20KR (K70R, K131R,
K163R, K224R, K231R, K311R, K328R, K453R, K462R, K474R,
K475R, K486R, K499R, K515R, K533R, K583R, K589R, K619R,
K682R, K709R) was produced as a synthetic gene (Thermo
Fisher, United States) and cloned into pEGFP-C3. Generation
of Pol  point mutants (K86R, K163R, K261R, K637R, K661R,
K683R, K686R, K694R, K709R) and the insertion of an extra
NLS sequence from SV40 large T antigen into pEGFP-C3 were
performed using site-directed mutagenesis (Q5 Site-directed
Mutagenesis Kit, New England Biolabs, United States). All con-
structs were verified by sequencing. Plasmid transfections were
done with FuGENE 6 (Roche Applied Science) or Genejuice
(Novagene) according to the manufacturers’ instructions.
siRNA transfections were performed using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s pro-
tocol. siRNA target sequences used in this study were: siCTRL,
5-GGGAUACCUAGACGUUCUA-3; siMMS21, 5-CUC-
UGGUAUGGACACAGCU-3; siPC2, 5-CGUGGGAACCG-
GAGGAGAA-3; siPIAS1#1, 5-UAAAGCUCUAGAAUGA-
UCC-3; siPIAS1#2, 5-UAGCUAUUUCACUGUCUGGAUC-
CGC-3; siPIAS1#3, 5-UAUUAAUGUAGCUUGUGUCUA-
CAGC-3; siPIAS1#4, 5-CGAAUGAACUUGGCAGAAA-3;
siPIAS2, 5-CUUGAAUAUUACAUCUUUA-3; siPIAS3, 5-
CCCUGAUGUCACCAUGAAA-3; siPIAS4#1, 5-CAAGAC-
AGGUGGAGUUGAU-3; siPol#1, 5-UAAACCUUGUGC-
AGUUGUA-3; siPol#2 (targeting the 3UTR), 5-GAGAAA-
GGGAAUUAUGAAA-3; siRAD6A, 5-GAACAAGCUGGC-
GUGAUU-3; siRAD6B, 5-CAAACGAGAAUAUGAGAAA-
3; siRAD18, 5-ACUCAGUGUCCAACUUGCU-3; siRanBP2,
5-GGACAGUGGGAUUGUAGUG-3; siRNF4#1, 5-GAAUG-
GACGUCUCAUCGUU-3; siRNF4#2, 5-GACAGAGACGUA-
UAUCUGA-3; siRNF111#1, 5-AGAAGGAAAUGAAUGG-
UAA-3; siRNF111#2, HS S182646 (Invitrogen, Thermo Scienti-
fic); siRNF111#3, GGAUAUUAAUGCAGAGGAA; siTopors,
5-CAAGGAGCCUGUCUAGUAA-3; siSAE1#1, 5-AGAAG-
AAACCAGAGUCAUU-3; siSAE1#2, 5-CAAAGUUAGC-
CAAGGAGUA-3; siUBA2#1, 5-GGAAAUUAGAUGAGA-
AAGA-3; siUBA2#2, 5-CCAAAUUGAAGAUGGGAAA-3;
Figure 4. Multisite SUMOylation of Pol  underlies its PIAS1- and RNF111-dependent extraction fromDNA damage sites. A, table showing identifica-
tion of endogenous Pol SUMOylation sites using an augmented K0-SUMOproteomic strategy coupledwith deepMSdata analysis. See also Table S3 and Fig.
S4.B, schematic diagramofhumanPol, depicting the locationof functionalmotifs and identifiedSUMOylation sites. Apreviously reportedPolSUMOylation
site, Lys-163 (37), which did not pass the significance threshold but was mutated along with the 19 high-confidence SUMOylation sites to generate the Pol 
20KRmutant, is indicated by the asterisk. C,U2OS cells or derivative clones stably expressing GFP-Pol WT or 20KRmutant (clone 1 (c1) and clone 2 (c2)) were
left untreated or exposed to UV, lysed, and subjected to GFP IP under denaturing conditions and immunoblotted (IB) with the indicated antibodies. D,
representative images of U2OS cells co-transfectedwith the indicatedGFP-Pol andHA-PIAS1 expression constructs, exposed toUV and immunostainedwith
HA antibody. Scale bar, 10 m. eV, empty vector. E, quantification of data in D (mean  S.E.M.; n  3 independent experiments; 55 cells analyzed per
condition). F, representative images of U2OS cells co-transfected with the indicated GFP-Pol  and HA-RNF111 expression constructs, exposed to UV, and
immunostained with HA antibody. Scale bar, 10 m. G, quantification of data in F (mean S.E.M.; n 3 independent experiments;100 cells analyzed per
condition).
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siUBC9#1, 5-GUAGCUGUCCCAACAAAGA-3; siUBC9#2, 5-
UCGAACCACCAUUAUUUCACCCGAA-3; and siUBC9#3,
5-GCUCAAGCAGAGGCCUACACGAUUU-3.
Cell culture
Human U2OS osteosarcoma cells, hTert RPE-1 retinal pig-
ment epithelial cells, and MRC5 fibroblast were obtained from
ATCC. U2OS andMRC5were cultured inDulbecco’smodified
Eagle’s medium and hTert RPE-1 in F-12/Dulbecco’s modified
Eagle’smedium containing 10% fetal bovine serum and 5%pen-
icillin-streptomycin. All cell lineswere regularly tested negative
formycoplasma infection. The U2OS cell line stably expressing
GFP-Pol  at a low and homogenous level was described previ-
ously (40). To generate cell lines stably expressing NLS-GFP-
Pol  WT or 20KR mutant, U2OS cells were co-transfected
with pBabe-Puro plasmid and expression constructs encoding
NLS-GFP-Pol  WT or 20KR, and subsequently selected with
Puromycin. Individual cloneswere screened forGFP-Polpos-
itivity bymicroscopy. Unless otherwise indicated, the following
concentrations of drugs and genotoxic agents were used: Cis-
platin (30 M for 6 h; Merck), UV radiation (UV; 20 J/m2), and
ML-792 (SUMO-E1i) (l M; MedKoo Biosciences).
Immunofluorescence, microscopy, and QIBC
Cells were pre-extracted in PBS containing 0.2% Triton
X-100 for 2 min on ice and fixed in 4% formaldehyde. For visu-
alization of endogenous Pol , pre-extraction was done in pre-
extraction buffer (10mMTris-HCl, pH 7.4, 2.5mMMgCl2, 0,5%
Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride) for 8 min
on ice, after which the cells were washed with PBS for 2 min on
ice and fixed in 4% formaldehyde. Immunofluorescence stain-
ing was performed by incubating fixed cells with primary or
secondary antibodies (Alexa Fluor; ThermoFisher Scientific)
diluted in PBS containing 10%BSA for 1 h at room temperature.
Cell cycle profiles were determined by pulse-labeling cells for
20 min with 10 M 5-ethynyl-2-deoxyuridine (EdU) immedi-
ately before pre-extraction and fixation. Staining was done
using the Click-iT Plus EdUAlexa Fluor 647 Imaging kit (Ther-
moFisher Scientific) according to the manufacturer’s instruc-
tions. Representative images were acquired with a confocal
microscope (LSM 880; Carl Zeiss), mounted on a confocal
laser-scanningmicroscope (Zeiss AxioObserver.Z1; Carl Zeiss)
equipped with a Plan Apochromat 40/1.3 NA oil immersion
objective. Image acquisition was performed with ZEN 2.1 soft-
ware (Carl Zeiss). QIBCwas performed as described previously
(42). Images were acquired using a wide-field microscope (IX-
81; Olympus) equipped with anMT20 Illumination system and
a digital monochrome charge-coupled device camera (C9100;
Hamamatsu Photonics). Olympus UPLSAPO 10/0.4 NA,
20/0.75 NA, and 40/0.95 NA objectives were used. Images
were acquired automatically and analyzed by the ScanR acqui-
sition and analysis software (Olympus).Datawere exported and
analyzed further using Spotfire (TIBCO Software Inc.).
siRNA screens
siRNA screens for regulators of Pol  foci formation were
performed by transfecting U2OS/GFP-Pol  WT cells with
siRNAs (10 nM final concentration) directly in 96-well
SCREENSTAR Microplates (Greiner Bio-one), using HiPer-
Fect transfection reagent (Qiagen) and an siRNA library target-
ing ubiquitin signaling factors (41) kindly provided by Claudia
Lukas (Novo Nordisk Foundation Center for Protein Research,
University of Copenhagen). After 48 h, cells were treated with
30 M cisplatin for 6 h and subsequently grown overnight in
freshmedium. Cells were then pre-extracted, fixed, and stained
with 4,6-diamidino-2-phenylindole. GFP-Pol  foci counts
were determined using QIBC, and ScanR analysis software was
used to calculate modified Z-scores, where the mean S.D. is
replaced by the median and median absolute deviation, as pre-
viously described (64).
Immunochemical methods
Immunoblotting and immunoprecipitation were done as
previously described (65). To obtain chromatin-enriched frac-
tions, cells were lysed in low-salt buffer (10 mMHEPES, pH 7.5,
10 mM KCl, 0.05% Nonidet P-40) and chromatin-associated
proteins were extracted from the pellet by treatment with
micrococcal nuclease in nuclease buffer (150 mM NaCl, 5 mM
CaCl2). To prepare whole cell extracts, cells were lysed in EBC
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
DTT, 0.5% Nonidet P-40, 1 mM DTT) supplemented with pro-
tease andphosphatase inhibitors. For detection of SUMOylated
proteins, cells were lysed in denaturing buffer (20 mM Tris, pH
7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% Nonidet P-40,
0.5% sodium deoxycholate, 0.5% SDS) containing protease and
phosphatase inhibitors and sonicated. GFP immunoprecipita-
tion was done using GFP-Trap-agarose beads (Chromotek).
Antibodies used in this study included: Actin (M1501; Milli-
pore), CPD (D194-1; MBL International), HA (F-7, sc-7392;
Santa Cruz Biotechnology), MCM6 (C-20, sc-9843; Santa Cruz
Biotechnology), PCNA (PC-10, sc-56; Santa Cruz Biotechnol-
ogy), Pol (A301–231A; Bethyl Laboratories), PIAS1 (ab77231;
Abcam), PIAS4 (D2F12, 4392S; Cell Signaling Technology),
RAD18 (ab57447; Abcam), SAE1 (A302-923A; Bethyl Labo-
ratories), SUMO1 (ab32058; Abcam), SUMO2/3 (ab3742;
Abcam), UBA2 (SAE2) (A302–925A; Bethyl Laboratories), and
UBC9 (ab21193;Abcam). Rabbit polyclonal RNF4 antibodywas
a kind gift from Alfred Vertegaal (Leiden University Medical
Center, Netherlands).
Quantification ofmRNA levels by RT-qPCR
RNAwas isolated from cells (RNeasy kit, Qiagen) and cDNA
was generated by PCRwith reverse transcription (iScript cDNA
Synthesis Kit, Bio-Rad) according to the manufacturer’s
instructions. Real-time quantitative PCR was performed using
the Stratagene Mx3005P System and Brilliant III Ultra-Fast
SYBR Green QPCRMaster Mix (Agilent). GAPDHmRNA lev-
els were used as a control for normalization. The following
primers were used for amplification of the indicated cDNAs:
GAPDH (forward), 5-CAGAACATCATCCCTGCCTCTAC-
3; GADPH (reverse), 5-TTGAAGTCAGAGGAGACCAC-
CTG-3; RNF111 (forward), 5-TGCATCCTCACTTGGCC-
CAT-3; RNF111 (reverse): 5-TCAGTTCCTCAAAATTGC-
CCCTG-3.
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Mass spectrometry
Analysis of Pol  SUMOylation sites was performed using
the enhanced K0-SUMO strategy, as described (52). The Pol 
SUMOylation sites reported here represent a subset of a larger
overarching dataset, which was independently published previ-
ously (52). MS proteomics RAW data are available at the
ProteomeXchange Consortium database via the Proteomics
Identifications (PRIDE) partner repository (ID PXD004927).
Briefly, HeLa and U2OS cell lines stably expressing K0-SUMO
(His10-SUMO2–8KR-Q87R-IRES-GFP) were cultured and
either mock treated or subjected to heat shock (43 °C for 1 h),
proteasome inhibition by MG132 (10 M, 8 h), or proteasome
inhibition by Bortezomib (100 nM, 24 h). Experiments were
performed in cell culture quadruplicates. Cells were lysed, after
which SUMOylated peptides were purified as described (52),
and trypsin-digested to yield peptides modified on lysine resi-
dueswith theQQTGGSUMO2/3mass remnant. Peptideswere
purified and fractionated into 6 fractions at high-pH on Stage-
Tips, prior toMS analysis.
All samples were analyzed on 15-cm long 75-m internal
diameter columns, packed in-house with ReproSil-Pur 120
C18-AQ 1.9-m beads (Dr. Maisch), connected to an EASY-
nLC 1200 system (Thermo). Fractionated samples were eluted
over 70-min analytical gradients increasing from 2 to 35% ace-
tonitrile in 0.1% fatty acid. The columnwas heated to 40 °C, and
samples were ionized using a Nanospray Flex Ion Source
(Thermo) and analyzed using a Q-Exactive HFmass spectrom-
eter (Thermo). Spray voltage was set to 2 kV, capillary temper-
ature set to 275 °C, and S-LensRF level set to 50%. For full scans,
a resolution setting of 60,000, an AGC target of 3,000,000, a
maximum injection time of 50 ms, and a scan range of 300–
1,750m/z was used. Precursors were fragmented using higher-
energy collision disassociation using a normalized collision
energy of 25, with the AGC target set at 100,000, and a precur-
sor isolation width of 1.3m/z. Unassigned charges, and charges
1 and 7, were excluded. A dynamic exclusion of 30 s was used.
MS2-level settings included a loop count of 7, resolution of
60,000, maximum injection time of 120 ms, and an underfill
ratio of 6% (50,000 intensity threshold).
All RAW files were analyzed in a single computational run
using MaxQuant software version 1.5.3.30. Default MaxQuant
settings were used for data analysis, with exceptions and
noteworthy default settings described below. For generation
of the theoretical peptide library, a FASTA database contain-
ing all human proteins was downloaded from UniProt on 28
July 2016, which contained 92,607 unique protein entries.
Trypsin was defined as the proteolytic enzyme (default),
maximum missed cleavages were set to 4, and maximum
number of variable modifications per peptide was set to 4,
with the following variable modifications: protein N-termi-
nal acetylation (default), methionine oxidation (default),
QQTGG on lysine (52), pyroQQTGG on lysine (52), and
phosphorylation on serine, threonine, and tyrosine. Mini-
mum peptide length was set to 6, maximum peptide mass
was set to 6,000. Data were automatically filtered at the pep-
tide-spectrum-match, protein, and site-identification levels
by posterior error probability to yield a false discovery rate of
1% (default), an MS1-level (precursor) mass tolerance of
4.5 ppm was applied (default), an MS2-level (fragment) mass
tolerance of 20 ppmwas applied (default), and modified pep-
tides were filtered for an Andromeda score of 40 (default)
and a delta score of6 (default). In addition, the SUMO site
output of MaxQuant was manually filtered for a localization
delta score of 6, the presence of QQTGG mass remnant
fragments (diagnostic peaks) in the MS/MS spectra, and the
absence of a reversed database hit.
Clonogenic survival assays
For colony formation assays, cells were transfected with
siRNAs, plated at low densities, and treated with UV at the
indicated doses, and subsequently incubated for 9 days in
medium supplemented with 0.4 mM caffeine. Cells were then
fixed and stained with crystal violet (0.5% (w/v) crystal violet,
25% (v/v) methanol). Colonies were counted using an auto-
mated colony counter (GelCount; Oxford Optronix). The sur-
viving fraction was calculated as number of colonies/(number
of seeded cellsplating efficiency) andnormalized to themock
control.
Data availability
Mass spectrometry proteomics RAWdata are available at the Pro-
teomeXchange Consortium database via the Proteomics Identifica-
tions (PRIDE) partner repository under dataset ID PXD004927. All
other data supporting the findings of this study are available within
the article and supporting information.
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